Itoh Seigo, Ding Bo, Bains Christopher P, Wang Nadan, Takeishi Yasuchika, Jalili Thunder, King George L, Walsh Richard A, Yan Chen, Abe Jun-ichi
Cardiovascular Research Institute, University of Rochester, Rochester, New York 14642, USA.
J Biol Chem. 2005 Jun 24;280(25):24135-42. doi: 10.1074/jbc.M413015200. Epub 2005 Apr 19.
Protein kinase C (PKC)-induced phosphorylation of cardiac troponin I (cTnI) depresses the acto-myosin interaction and may be important during the progression of heart failure. Although both PKCbetaII and PKCepsilon can phosphorylate cTnI, only PKCbeta expression and activity are elevated in failing human myocardium during end-stage heart failure. Furthermore, although increased cTnI phosphorylation was observed in mice with cardiac-specific PKCbeta II overexpression, no differences were observed in cTnI phosphorylation status between wild type and cardiac-specific PKCepsilon overexpression mice. A potentially important downstream effector of PKCs is p90 ribosomal S6 kinase (p90RSK), which plays an important role in cell growth by activating several transcription factors as well as Na+/H+ exchanger. Since both Ser23 and Ser24 of cTnI are contained in putative consensus sequences of p90RSK phosphorylation sites, we hypothesized that p90RSK is downstream from PKCbeta II and can be a cTnI (Ser(23/24)) kinase. p90RSK, but not ERK1/2 activation, was increased in PKCbetaII overexpression mice but not in PKCepsilon overexpression mice. p90RSK could phosphorylate cTnI in vitro with high substrate affinity but not cardiac troponin T (cTnT). To confirm the role of p90RSK in cTnI phosphorylation in vivo, we generated adenovirus containing a dominant negative form of p90RSK (Ad-DN-p90RSK). We found that the inhibition of p90RSK prevented H2O2-mediated cTnI (Ser(23/24)) phosphorylation but not ERK1/2 and PKCalpha/betaII activation. Next, we generated cardiac-specific p90RSK transgenic mice and observed that cTnI (Ser(23/24)) phosphorylation was significantly increased. LY333,531, a specific PKCbeta inhibitor, inhibited both p90RSK and cTnI (Ser(23/24)) phosphorylation by H2O2. Taken together, our data support a new redox-sensitive mechanism regulating cTnI phosphorylation in cardiomyocytes.
蛋白激酶C(PKC)诱导的心肌肌钙蛋白I(cTnI)磷酸化会抑制肌动蛋白-肌球蛋白相互作用,这在心力衰竭进展过程中可能很重要。尽管PKCβII和PKCε都能使cTnI磷酸化,但在终末期心力衰竭患者的衰竭心肌中,只有PKCβ的表达和活性升高。此外,尽管在心脏特异性PKCβII过表达的小鼠中观察到cTnI磷酸化增加,但在野生型和心脏特异性PKCε过表达小鼠之间,cTnI磷酸化状态没有差异。PKC的一个潜在重要下游效应器是p90核糖体S6激酶(p90RSK),它通过激活多种转录因子以及Na+/H+交换体在细胞生长中起重要作用。由于cTnI的Ser23和Ser24都包含在p90RSK磷酸化位点的假定共有序列中,我们推测p90RSK在PKCβII下游,可能是cTnI(Ser(23/24))激酶。在PKCβII过表达小鼠中,p90RSK而非ERK1/2的激活增加,而在PKCε过表达小鼠中未增加。p90RSK在体外能以高底物亲和力使cTnI磷酸化,但不能使心肌肌钙蛋白T(cTnT)磷酸化。为了在体内证实p90RSK在cTnI磷酸化中的作用,我们构建了含有p90RSK显性负性形式的腺病毒(Ad-DN-p90RSK)。我们发现抑制p90RSK可阻止H2O2介导的cTnI(Ser(23/24))磷酸化,但不影响ERK1/2和PKCα/βII的激活。接下来,我们构建了心脏特异性p90RSK转基因小鼠,观察到cTnI(Ser(23/24))磷酸化显著增加。LY333,531是一种特异性PKCβ抑制剂,可抑制H2O2诱导的p90RSK和cTnI(Ser(23/24))磷酸化。综上所述,我们的数据支持一种新的氧化还原敏感机制来调节心肌细胞中cTnI的磷酸化。